Current Report Filing (8-k)
23 April 2020 - 9:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 23, 2020
Baudax Bio, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Pennsylvania
|
|
001-39101
|
|
47-4639500
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
490 Lapp Road,
Malvern, Pennsylvania
|
|
19355
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (484)
395-2470
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(g) of the Act:
None
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class
|
|
Trading
Symbol
|
|
Name of Exchange
on Which Registered
|
Common Stock, par value $0.01
|
|
BXRX
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 8.01 Other Events.
On April 23, 2020, Baudax Bio, Inc. issued a press release announcing two virtual poster presentations highlighting new ANJESO injection data at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting, hosted by the American Society of Regional
Anesthesia and Pain Medicine. A copy of the press release is attached hereto as Exhibit 99.1, and incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are being filed herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
Baudax Bio, Inc.
|
|
|
By:
|
|
/s/ Gerri A. Henwood
|
Name:
|
|
Gerri A. Henwood
|
Title:
|
|
Chief Executive Officer
|
Date: April 23, 2020
Baudax Bio (NASDAQ:BXRXV)
Historical Stock Chart
From May 2024 to Jun 2024
Baudax Bio (NASDAQ:BXRXV)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Baudax Bio Inc (NASDAQ): 0 recent articles
More Baudax Bio, Inc. News Articles